Search Results for: Schizophrenia

1632 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
ACTG1 and TNIK actin gamma 1 TRAF2 and NCK interacting kinase
  • Axon guidance
  • Gap junction degradation
  • Adherens junctions interactions
  • Translocation of GLUT4 to the plasma membrane
  • L1CAM interactions
  • Recycling pathway of L1
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • Interaction between L1 and Ankyrins
  • Cell-cell junction organization
  • EPH-ephrin mediated repulsion of cells
  • Gap junction trafficking and regulation
  • EPH-Ephrin signaling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Regulation of actin dynamics for phagocytic cup formation
  • Innate Immune System
  • Cell junction organization
  • Formation of annular gap junctions
  • Gap junction trafficking
  • Signaling by VEGF
  • Cell-extracellular matrix interactions
  • Oxidative Stress Induced Senescence
  • Cellular Senescence
ACTG1 and DISC1 actin gamma 1 disrupted in schizophrenia 1
  • Axon guidance
  • Gap junction degradation
  • Adherens junctions interactions
  • Translocation of GLUT4 to the plasma membrane
  • L1CAM interactions
  • Recycling pathway of L1
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • Interaction between L1 and Ankyrins
  • Cell-cell junction organization
  • EPH-ephrin mediated repulsion of cells
  • Gap junction trafficking and regulation
  • EPH-Ephrin signaling
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Regulation of actin dynamics for phagocytic cup formation
  • Innate Immune System
  • Cell junction organization
  • Formation of annular gap junctions
  • Gap junction trafficking
  • Signaling by VEGF
  • Cell-extracellular matrix interactions
ACTL6A and SMARCA2 actin-like 6A SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2
  • Chromatin modifying enzymes
  • Chromatin organization
  • HATs acetylate histones
  • RMTs methylate histone arginines
  • Chromatin modifying enzymes
  • Chromatin organization
  • RMTs methylate histone arginines
ACTN1 and GRIN2A actinin, alpha 1 glutamate receptor, ionotropic, N-methyl D-aspartate 2A
  • Cell junction organization
  • Syndecan interactions
  • Response to elevated platelet cytosolic Ca2+
  • Regulation of cytoskeletal remodeling and cell spreading by IPP complex components
  • Nephrin interactions
  • Platelet degranulation
  • Non-integrin membrane-ECM interactions
  • Platelet activation, signaling and aggregation
  • Cell-extracellular matrix interactions
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • CREB phosphorylation through the activation of CaMKII
  • CREB phosphorylation through the activation of Ras
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Unblocking of NMDA receptor, glutamate binding and activation
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Post NMDA receptor activation events
  • Transmission across Chemical Synapses
  • L-Glutamic Acid
  • Glycine
  • Meperidine
  • Felbamate
  • Memantine
  • Halothane
  • Tenocyclidine
ACTN2 and DISC1 actinin, alpha 2 disrupted in schizophrenia 1
  • Striated Muscle Contraction
  • Platelet degranulation
  • CREB phosphorylation through the activation of Ras
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • Response to elevated platelet cytosolic Ca2+
  • CREB phosphorylation through the activation of CaMKII
  • Nephrin interactions
  • Platelet activation, signaling and aggregation
  • Unblocking of NMDA receptor, glutamate binding and activation
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Transmission across Chemical Synapses
  • Post NMDA receptor activation events
ACVR1 and DCAF6 activin A receptor, type I DDB1 and CUL4 associated factor 6
  • Adenosine triphosphate
  • 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine
ACVR1B and BAG6 activin A receptor, type IB BCL2-associated athanogene 6
  • Signaling by Activin
  • Regulation of signaling by NODAL
  • Signaling by NODAL
  • Adenosine triphosphate
ACY1 and NUDT1 aminoacylase 1 nudix (nucleoside diphosphate linked moiety X)-type motif 1
  • Aflatoxin activation and detoxification
  • Biological oxidations
  • Metabolic disorders of biological oxidation enzymes
  • Defective ACY1 causes encephalopathy
  • L-Aspartic Acid
ADM and EDN1 adrenomedullin endothelin 1
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • GPCR downstream signaling
  • G alpha (s) signalling events
  • Calcitonin-like ligand receptors
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Class B/2 (Secretin family receptors)
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • G alpha (q) signalling events
  • G alpha (q) signalling events
  • Signaling by GPCR
  • GPCR downstream signaling
  • Peptide ligand-binding receptors
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Class A/1 (Rhodopsin-like receptors)
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
ADM and CFH adrenomedullin complement factor H
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • GPCR downstream signaling
  • G alpha (s) signalling events
  • Calcitonin-like ligand receptors
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Class B/2 (Secretin family receptors)
  • Regulation of Complement cascade
  • Complement cascade
  • Innate Immune System
ADM and CALCRL adrenomedullin calcitonin receptor-like
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • GPCR downstream signaling
  • G alpha (s) signalling events
  • Calcitonin-like ligand receptors
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Class B/2 (Secretin family receptors)
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • GPCR downstream signaling
  • G alpha (s) signalling events
  • Calcitonin-like ligand receptors
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Class B/2 (Secretin family receptors)
ADM and MME adrenomedullin membrane metallo-endopeptidase
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • GPCR downstream signaling
  • G alpha (s) signalling events
  • Calcitonin-like ligand receptors
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Class B/2 (Secretin family receptors)
  • Peptide hormone metabolism
  • Metabolism of Angiotensinogen to Angiotensins
  • Candoxatril
  • N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1\'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine
  • Phosphoramidon
  • N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine
  • [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala
  • 2-[(1S)-1-BENZYL-2-SULFANYLETHYL]-1H-IMIDAZO[4,5-C]PYRIDIN-5-IUM
  • Thiorphan
PARP1 and NFKB1 poly (ADP-ribose) polymerase 1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • TGFBR1 LBD Mutants in Cancer
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Loss of Function of TGFBR1 in Cancer
  • Generic Transcription Pathway
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
  • Signaling by the B Cell Receptor (BCR)
  • NF-kB is activated and signals survival
  • Downstream TCR signaling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Cellular Senescence
  • RIP-mediated NFkB activation via ZBP1
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Downstream signaling events of B Cell Receptor (BCR)
  • FCERI mediated NF-kB activation
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • ZBP1(DAI) mediated induction of type I IFNs
  • p75NTR signals via NF-kB
  • Transcriptional regulation of white adipocyte differentiation
  • MyD88 dependent cascade initiated on endosome
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • Innate Immune System
  • Regulated proteolysis of p75NTR
  • Signalling by NGF
  • TRIF-mediated TLR3/TLR4 signaling
  • Cytosolic sensors of pathogen-associated DNA
  • Senescence-Associated Secretory Phenotype (SASP)
  • Cytokine Signaling in Immune system
  • p75 NTR receptor-mediated signalling
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Signaling by Interleukins
  • TCR signaling
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Interleukin-1 processing
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Activation of NF-kappaB in B cells
  • Fc epsilon receptor (FCERI) signaling
  • TRAF6 mediated NF-kB activation
  • Interleukin-1 signaling
  • Adaptive Immune System
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Carba-Nicotinamide-Adenine-Dinucleotide
  • NU1025
  • Nicotinamide
  • 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
  • 3-Methoxybenzamide
  • 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
  • 3,4-Dihydro-5-Methyl-Isoquinolinone
  • 2-(3\'-Methoxyphenyl) Benzimidazole-4-Carboxamide
  • 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
  • (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
  • trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium
  • 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
  • Thalidomide
  • Pranlukast
  • Triflusal
PARP1 and TCF4 poly (ADP-ribose) polymerase 1 transcription factor 4
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • TGFBR1 LBD Mutants in Cancer
  • Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
  • Loss of Function of TGFBR1 in Cancer
  • Generic Transcription Pathway
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • SMAD4 MH2 Domain Mutants in Cancer
  • CDO in myogenesis
  • Myogenesis
  • Carba-Nicotinamide-Adenine-Dinucleotide
  • NU1025
  • Nicotinamide
  • 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
  • 3-Methoxybenzamide
  • 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
  • 3,4-Dihydro-5-Methyl-Isoquinolinone
  • 2-(3\'-Methoxyphenyl) Benzimidazole-4-Carboxamide
  • 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
  • (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
  • trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium
  • 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
AES and TRIM26 amino-terminal enhancer of split tripartite motif containing 26
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Signaling by Wnt
  • repression of WNT target genes
  • APC truncation mutants are not K63 polyubiquitinated
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • truncations of AMER1 destabilize the destruction complex
  • Interferon gamma signaling
  • Interferon Signaling
  • Cytokine Signaling in Immune system
AES and TCF4 amino-terminal enhancer of split transcription factor 4
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Signaling by Wnt
  • repression of WNT target genes
  • APC truncation mutants are not K63 polyubiquitinated
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • Myogenesis
NR0B1 and RORA nuclear receptor subfamily 0, group B, member 1 RAR-related orphan receptor A
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • REV-ERBA represses gene expression
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • RORA activates circadian gene expression
  • Tretinoin
  • Dexamethasone
AHR and ARNTL aryl hydrocarbon receptor aryl hydrocarbon receptor nuclear translocator-like
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • REV-ERBA represses gene expression
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • RORA activates circadian gene expression
ALOX5 and MAD1L1 arachidonate 5-lipoxygenase MAD1 mitotic arrest deficient-like 1 (yeast)
  • Arachidonic acid metabolism
  • Synthesis of 5-eicosatetraenoic acids
  • Metabolism of lipids and lipoproteins
  • Synthesis of Lipoxins (LX)
  • Synthesis of Leukotrienes (LT) and Eoxins (EX)
  • Mitotic Spindle Checkpoint
  • Amplification of signal from the kinetochores
  • Mitotic Prometaphase
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Cell Cycle Checkpoints
  • Mitotic Anaphase
  • Mitotic Metaphase and Anaphase
  • Cell Cycle, Mitotic
  • M Phase
  • Vitamin E
  • Masoprocol
  • Aminosalicylic Acid
  • Mesalazine
  • Montelukast
  • Diclofenac
  • Diethylcarbamazine
  • Zileuton
  • Sulfasalazine
  • Meclofenamic acid
  • Balsalazide
  • Minocycline
  • Hyperforin
  • Heme
ALPL and TRAF3 alkaline phosphatase, liver/bone/kidney TNF receptor-associated factor 3
  • Activated TLR4 signalling
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • TRAF3-dependent IRF activation pathway
  • Toll-Like Receptors Cascades
  • Negative regulators of RIG-I/MDA5 signaling
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • MyD88-independent cascade
  • Innate Immune System
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon

Page 2 out of 82 pages